Photo: OGphoto/Getty
People with ultra-high-risk multiple myeloma may respond poorly to treatment, relapse quickly after they have had chemotherapy, and have a poor prognosis. However, new treatment options such as chimeric antigen receptor (CAR) T-cell therapy and bispecific antibody approaches are showing promise for these patients, says Gareth J. Morgan, MD, PhD, professor in the at NYU Grossman School of Medicine and director of multiple myeloma research at 抖阴短视频 Health鈥檚 Perlmutter Cancer Center.
鈥淭he results we see in relapsed/refractory patients with these agents really suggest they鈥檙e going to be game changers for ultra-high-risk myeloma,鈥 Dr. Morgan says. 鈥淎nd it鈥檚 making me very excited for the change that it鈥檚 going to bring about for patients.鈥
Watch and read more from .
听
